How India Exports Folic to the World

In the United States, folic acid is approved for various therapeutic uses, including the treatment of megaloblastic anemias due to folic acid deficiency and as a supplement during pregnancy to prevent neural tube defects. The FDA Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for folic acid tablets, indicating a well-established generic market. For instance, Premo Pharmaceutical Laboratories, Inc. received approval for Folic Acid Tablets 1 mg (ANDA 84-472) on June 16, 1976.

Given the presence of 693 active Indian exporters supplying folic acid globally, it is evident that Indian manufacturers are significant contributors to the U.S. market. To export folic acid to the U.S., Indian companies must comply with the FDA's regulatory requirements, including facility registration, product listing, and adherence to Current Good Manufacturing Practices (cGMP). Additionally, if the product is intended for therapeutic use, obtaining an approved ANDA is essential.

In the European Union, folic acid is subject to marketing authorization by the European Medicines Agency (EMA). While specific marketing authorizations for folic acid as a standalone product are limited, it is often included in combination therapies. For example, the EMA granted orphan designation to folic acid for use with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine for the diagnosis of positive folate-receptor status in ovarian cancer on September 10, 2012. (ema.europa.eu)

In the United Kingdom, the Food Standards Agency (FSA) announced on October 8, 2025, that non-wholemeal wheat flour will be fortified with folic acid by law from December 2026. This measure aims to prevent neural tube defects in newborns. (food.gov.uk)

Manufacturers exporting to the EU and UK must comply with Good Manufacturing Practice (GMP) standards and ensure that their products meet the specific regulatory requirements of each member state.

Folic acid is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in public health. It is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, safety, and efficacy of folic acid products in the global market.

In India, folic acid is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including folic acid, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

Folic acid is a well-established compound with no active patents, allowing for extensive generic competition. This has led to a competitive market with multiple manufacturers producing and exporting folic acid globally.

In November 2024, the UK government announced legislation requiring the fortification of non-wholemeal wheat flour with folic acid by the end of 2026, aiming to prevent around 200 cases of neural tube defects annually. (gov.uk)

On June 6, 2025, the UK's Food Standards Agency added folic acid to the register of authorized feed additives, reflecting its recognized safety and efficacy. (food.gov.uk)

These developments indicate a growing global emphasis on the importance of folic acid in public health initiatives, potentially influencing demand and regulatory landscapes for exporters.

India's pharmaceutical industry, including the production of folic acid, has historically relied heavily on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). As of October 2025, approximately 41% of KSMs used in U.S.-approved medicines were sourced solely from China, with an additional 16% coming exclusively from India. This concentration poses significant risks of supply chain disruptions due to geopolitical tensions, export restrictions, or natural disasters.

To mitigate these vulnerabilities, the Indian government launched the Production Linked Incentive (PLI) Scheme for Bulk Drugs in July 2020, aiming to promote domestic manufacturing of critical KSMs, DIs, and APIs. By September 2025, this initiative had led to the establishment of production capacities for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore, including exports of ₹508 crore, thereby avoiding imports worth ₹1,807 crore.

The export market for folic acid from India is moderately concentrated. The top five exporters—UMAVIDA PHARMA PRIVATE LIMITED, GRACURE PHARMACEUTICALS LIMITED, STRIDES PHARMA SCIENCE LIMITED, CADILA PHARMACEUTICALS LIMITED, and MEDICAMEN BIOTECH LIMITED—collectively account for 25.7% of total exports, with UMAVIDA PHARMA PRIVATE LIMITED leading at a 6.5% share. This distribution indicates a relatively low risk of over-reliance on a single supplier.

The PLI Scheme for Pharmaceuticals, initiated in March 2021, aims to further diversify and strengthen the pharmaceutical manufacturing base in India. By September 2025, the scheme had attracted a committed investment of ₹17,275 crore, surpassing the initial target, and had already achieved an actual investment of ₹40,890 crore. This substantial investment is expected to enhance production capabilities and reduce single-source dependency risks.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceuticals. Any geopolitical tensions or conflicts in these regions can lead to delays and increased shipping costs. Additionally, ongoing U.S.-China trade tensions have the potential to disrupt the supply of raw materials essential for pharmaceutical manufacturing.

As of March 2026, there have been no specific shortage alerts issued by the FDA or EMA concerning folic acid. However, the interconnected nature of global supply chains necessitates continuous monitoring to preemptively address potential disruptions.

• Diversify Supplier Base: Engage with a broader range of suppliers to reduce dependency on a limited number of exporters.

• Strengthen Domestic Manufacturing: Leverage government incentives, such as the PLI schemes, to enhance local production capacities for APIs and KSMs.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could impact shipping routes and raw material availability.

• Develop Contingency Plans: Create and regularly update contingency strategies to address potential supply chain disruptions.

• Enhance Supply Chain Transparency: Implement advanced tracking systems to gain real-time insights into the movement of raw materials and finished products.

RISK_LEVEL: MEDIUM